We asked whether PAM50 subtyping of the PDXs, which has been applied to other tumor types outside of breast cancer,23,24 or the presence of genomic alterations in MAP3K1 or PIK3CA were associated with an improved response in vivo to PI3K inhibition. The gene discussed is MAP3K1; the disease is breast cancer.